Sunday, December 4, 2022
Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development...
Read more
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range...
Read more
InMed Pharmaceuticals (NASDAQ: INM) Says Research Grant to Test Cannabinoid Analogs as a Potential Treatment for Alzheimer’s, Parkinson’s and Huntington’s Disease
InMed Pharmaceuticals, Inc. (NASDAQ: INM) is a pharmaceutical research and development company that is focused on utilizing cannabinoids and related...
Read more
Opiant Pharmaceuticals (NASDAQ: OPNT) Enters Into Definitive Agreement to be Acquired by Indivior for $145 Million
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is engaged as a specialty pharmaceutical company, which is focused on developing treatments for drug...
Read more
Outset Medical (NASDAQ: OM) Releases Third Quarter 2022 Financial Results Showing Modest Revenue Growth Y/Y
Outset Medical, Inc. (NASDAQ: OM) is engaged as a medical technology company, which is focused on the research and development...
Read more
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development...
Read more
Virax Biolabs (NASDAQ: VRAX) Launches Triple Virus Antigen Test Kit For RSV, Flu and COVID
Virax Biolabs, Inc. (NASDAQ: VRAX) is engaged as a biotechnology company, which is focused on the prevention, detection and diagnosis...
Read more
Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR
Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to...
Read more
Electromedical Technologies (OTCQB: EMED) Unveils the WellnessPro Infinity Bioelectronic Device
Electromedical Technologies, Inc. (OTCQB: EMED) is engaged as a commercial-stage bioelectronic medical device company, which is focused on developing treatments...
Read more
Hoth Therapeutics (NASDAQ: HOTH) Releases BioLexa Phase 1B Trial Results Showing Positive Results in Treating Mild to Moderate Atopic Dermatitis
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development...
Read more
